KERUIHK-0101Best SellerSemaglutide
GMPGLP-1 receptor agonist for type 2 diabetes and chronic weight management. Widely used in clinical and wellness protocols.
KERUIHK-0101Best SellerGLP-1 receptor agonist for type 2 diabetes and chronic weight management. Widely used in clinical and wellness protocols.
KERUIHK-0102HotDual GIP/GLP-1 receptor agonist. Superior weight loss efficacy with improved glycemic control in clinical trials.
KERUIHK-0103NewLong-acting amylin analogue for appetite suppression and weight reduction. Often combined with semaglutide.
KERUIHK-0104NewTriple agonist targeting GLP-1, GIP, and glucagon receptors. Promising next-generation obesity treatment.
KERUIHK-0105
KERUIHK-0106GMPNative GLP-1 receptor agonist. Regulates glucose-dependent insulin secretion and gastric emptying.
KERUIHK-0107New
KERUIHK-0108GLP-1/glucagon receptor dual agonist. Investigated for obesity and metabolic-associated steatohepatitis (MASH).
KERUIHK-0109GMPGLP-1 receptor agonist with C16 fatty acid conjugation for extended half-life. Proven weight management therapy.
We synthesize any sequence at any scale — from milligram research quantities to multi-kilogram commercial batches. OEM, private label, and GMP manufacturing available. Response within 24 hours.